Phaseline

Companies › Pharmbio Korea

Pharmbio Korea: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PBK_M2301
Combination of levodropropizine (antitussive) and Pelargonium sidoides extract
–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07161180PBK_M2301Phase 1Healthy VolunteersOtherOct 2025

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.